Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF) - A phase II trial

被引:82
作者
Mavroudis, D [1 ]
Kourousis, C [1 ]
Androulakis, N [1 ]
Kalbakis, K [1 ]
Agelaki, S [1 ]
Kakolyris, S [1 ]
Souglakos, J [1 ]
Sarra, E [1 ]
Vardakis, N [1 ]
Hatzidaki, D [1 ]
Sarmonis, G [1 ]
Georgoulias, V [1 ]
机构
[1] Univ Gen Hosp Heraklion, Dept Med Oncol, Heraklion 71110, Crete, Greece
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2000年 / 23卷 / 04期
关键词
docetaxel; G-CSF; advanced gastric cancer;
D O I
10.1097/00000421-200008000-00005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We conducted a phase II study to evaluate the efficacy and tolerance of docetaxel monotherapy with granulocyte colony-stimulating factor (G-CSF) support in patients with advanced gastric cancer. Thirty patients with measurable advanced gastric cancer were enrolled. Twenty-four patients were chemotherapy-naive and six patients had previously received adjuvant chemotherapy after complete surgical resection. Docetaxel was administered at 100 mg/m(2) IV during 1 hour every 3 weeks. G-CSF 5 mu g/kg SC was also given on days 2 through 8 prophylactically to all patients. All patients were evaluable for response and toxicity. We observed one complete and five partial responses for an overall response rate of 20% (95% confidence interval: 6-34%). In addition, seven patients (23%) had stable disease. After a median follow-up time of 7 months, the median duration of response was 4.5 months, the median time of tumor progression was 6 months, and the median survival was 7 months. The estimated probability of 1-year survival was 28%. Toxicity was generally mild. Grade III/IV neutropenia occurred in 11 (36%) patients. Neutropenia with fever developed in three patients (10%). There were no toxic deaths. Docetaxel with G-CSF support is an active drug and well tolerated by patients with advanced gastric cancer. Docetaxel merits further investigation in combination with other active agents as frontline treatment in patients with advanced gastric cancer.
引用
收藏
页码:341 / 344
页数:4
相关论文
共 20 条
  • [1] COMPREHENSIVE CRITERIA FOR ASSESSING THERAPY-INDUCED TOXICITY
    AJANI, JA
    WELCH, SR
    RABER, MN
    FIELDS, WS
    KRAKOFF, IH
    [J]. CANCER INVESTIGATION, 1990, 8 (02) : 147 - 159
  • [2] Ajani JA, 1998, CANCER J SCI AM, V4, P269
  • [3] [Anonymous], 1989, Analysis of binary data
  • [4] CONTROLLED EVALUATION OF 3 DRUG-COMBINATION REGIMENS VERSUS FLUOROURACIL ALONE FOR THE THERAPY OF ADVANCED GASTRIC-CANCER
    CULLINAN, SA
    MOERTEL, CG
    WIEAND, HS
    OCONNELL, MJ
    POON, MA
    KROOK, JE
    MAILLIARD, JA
    TSCHETTER, LK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (02) : 412 - 416
  • [5] Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The eastern cooperative oncology group (ECOG) results of protocol E1293
    Einzig, AI
    Neuberg, D
    Remick, SC
    Karp, DD
    ODwyer, PJ
    Stewart, JA
    Benson, AB
    [J]. MEDICAL ONCOLOGY, 1996, 13 (02): : 87 - 93
  • [6] MEDICAL PROGRESS - GASTRIC-CARCINOMA
    FUCHS, CS
    MAYER, RJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (01) : 32 - 41
  • [7] GILBERT C, 1998, P AN M AM SOC CLIN, V17, pA91
  • [8] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS
    KAPLAN, EL
    MEIER, P
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) : 457 - 481
  • [9] KELSEN D, 1988, ISRAEL J MED SCI, V24, P557
  • [10] MILLER VA, 1995, CANCER-AM CANCER SOC, V75, P968, DOI 10.1002/1097-0142(19950215)75:4<968::AID-CNCR2820750411>3.0.CO